Compare Pfizer Inc (PFE) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Under Armour Inc Class A — how do they compare? Pfizer Inc trades at $27.88 (market cap $158.39B), while Under Armour Inc Class A trades at $4.92 (market cap $2.15B). The key difference: Pfizer Inc is far larger — about 73.7× Under Armour Inc Class A's market cap, and Pfizer Inc pays a 6.19% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| PFE | UAA | |
|---|---|---|
Market Cap | $158.39B | $2.15B |
Volume | 29,869,932 | — |
Sector | Health | Consumer Cyclical |
52-Week High | $29.02 | $8.14 |
52-Week Low | $23.60 | $4.17 |
Enterprise Value | $209.89B | $3.13B |
Dividend Yield | 6.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.
Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.
Under Armour (UAA) trades at $5.06, down 3.62% amid bearish technical signals and negative cash flow. The company reported Q2 2026 EPS of $0.05, beating expectations, but faces revenue declines and a net loss of $201 million in 2025. Analyst consensus is mixed with 27% buy ratings and a $6.67 price target, while technical indicators show resistance at $5 with RSI neutral but ADX signaling strong bearish momentum.
UAA's outlook is challenged by weakening revenue and negative profitability, though cost controls and international growth offer some support. Investment opportunity exists if margin improvements translate to sustained earnings, but risks include persistent North America softness and high debt levels. The stock trades near analyst low targets, suggesting limited upside without operational turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
